Prostate Cancer: Low-volume Centers Less Likely to Employ Active Surveillance

Share this content:
Researchers evaluated data from 115,208 patients with low-risk prostate cancer diagnosed between 2010 and 2014 to determine the frequency of active surveillance and factors associated with receipt of
Researchers evaluated data from 115,208 patients with low-risk prostate cancer diagnosed between 2010 and 2014 to determine the frequency of active surveillance and factors associated with receipt of

Among patients with low-risk prostate cancer, active surveillance has become an increasingly common strategy since 2010, though with considerable variability among institutions, according to research published in Cancer.1

Active surveillance has emerged as the recommended treatment strategy for patients with low-risk disease; surveillance includes regular testing (prostate specific antigen [PSA], biopsies, and physical examinations) until disease progression, after which patients begin therapy. There is, however, variation among institutions regarding how often active surveillance is employed.

For this retrospective study, researchers evaluated data from 115,208 patients with low-risk prostate cancer diagnosed between 2010 and 2014 to determine the frequency of active surveillance and factors associated with receipt of the treatment strategy.

In 2010, 6.8% of patients received active surveillance; this figure increased to 19.9% by 2014, indicating a 28.8% annual percentage increase. Patients at community cancer centers were twice as likely (odds ratio [OR], 2.00; P < .001) to receive active surveillance as those treated at comprehensive community cancer centers. Patients at academic institutions had an OR for active surveillance of 2.47 (P < .001) vs comprehensive community cancer centers.

The OR for active surveillance in high-volume cancer centers vs low-volume centers was 3.57 (P < .001).

The authors concluded that policies “to achieve consistent and higher rates of active surveillance, when appropriate, should be a priority of professional societies and patient advocacy groups.”

Reference

  1. Löppenberg B, Friedlander DF, Krasnova A, et al. Variation in the use of active surveillance for low-risk prostate cancer. Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters